Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Shattuck Labs, Inc. - Common Stock
(NQ:
STTK
)
1.140
+0.080 (+7.55%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 6, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Shattuck Labs, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights
May 01, 2025
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference
April 02, 2025
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
March 27, 2025
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
February 20, 2025
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
February 13, 2025
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn’s and Colitis Congress
February 04, 2025
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
January 06, 2025
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025
January 02, 2025
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces Participation in Upcoming December Conferences
November 25, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 14, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
STTK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Shattuck Labs, Inc. and Encourages Investors to Contact the Firm
October 29, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
STTK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Shattuck Labs, Inc. and Encourages Investors to Contact the Firm
October 28, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
STTK is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
October 04, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
STTK is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
October 04, 2024
NEW YORK, NY - (NewMediaWire) - October 04, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ:...
Via
TheNewswire.com
Kaplan Fox & Kilsheimer LLP is Investigating Potential Securities Law Violations Against Shattuck Labs, Inc. (STTK)
October 03, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Kaplan Fox & Kilsheimer LLP is Investigating Potential Securities Law Violations Against Shattuck Labs, Inc. (STTK)
October 03, 2024
NEW YORK, NY - (NewMediaWire) - October 03, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ:...
Via
TheNewswire.com
Kaplan Fox & Kilsheimer LLP is Investigating Shattuck Labs, Inc. (STTK) for Potential Securities Law Violations
October 02, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Kaplan Fox & Kilsheimer LLP is Investigating Shattuck Labs, Inc. (STTK) for Potential Securities Law Violations
October 02, 2024
NEW YORK, NY - (NewMediaWire) - October 02, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ:...
Via
TheNewswire.com
Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway
October 01, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 01, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference
July 30, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes
July 01, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid
June 14, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)
June 10, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk
June 06, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the
May 14, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 02, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
April 09, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference
April 01, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors
March 04, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.